zurück Home

Prostata - Karzinom: Taxan - Studien

Allgemeines

Eine Chemotherapie mit Docetaxel kann die Überlebenszeit eines metastasierten HRPCs verlängern (1: Metaanalyse).

Studien

StudieRekrutierungPatientenKontroll-ArmPrüf-ArmBemerkungen
GETUG-12 (6,7)2002–2006 413 Goserelin 10,8 mg alle 3M 3a + Docetaxel 70 mg/qm 4x + Estramustin M0 
TAX 3501 (8) 2005–2007 228 Leuprolide 22,5 mg alle 3M 18M + Docetaxel 75 mg/qm 6x M0
RTOG 0521 (9) 2005–2009 612 LHRH + Antiandrogen + RT) + Docetaxel 75 mg/qm 6x + Prednison M0
STAMPEDE (+-docetaxel) (3)2005–2013 1776 ADT + RT+ Docetaxel 75 mg/qm 6x + Predison M0 und M1
STAMPEDE (zoledron +- docetaxel) (3)2005–2013 1186 ADT + RT + Zoledro 4 mg alle 3-4W 2a + Docetaxel 75 mg/qm 6x M0 und M1
GETUG-15 (4,5)2004–2008 385 LHRH oder Kastration oder duale Blockade + Docetaxel 75 mg/qm bis 9x M1
CHAARTED (2) 2006–2012 790 LHRH oder Kastration  + Docetaxel 75 mg/qm 6x M1

Quelle

1.) Vale CL, et al., for the STOpCaP Steering Group:
Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data.
Lancet Oncol 2016;17):243–256. Doi: 10.1016/S1470-2045(15)00489-1

2.)  Sweeney CJ, Chen Y-H, Carducci M:
Chemohormonal therapy in metastatic hormone-sensitive prostate cancer.
N Engl J Med. 2015;373:737–746

3. ) James ND, Sydes MR, Clarke NW:
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
Lancet 2015 http://dx.doi.org/10.1016/S0140-6736(15)01037-5

4.)  Gravis G, Fizazi K, Joly F:
Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.
Lancet Oncol. 2013;14:149–158

5.)  Gravis G, Boher JM, Joly F:
Androgen deprivation therapy (ADT) plus docetaxel (D) versus ADT alone for hormone-naïve metastatic prostate cancer (PCa): long-term analysis of the GETUG-AFU 15 phase III trial.
Proc Am Soc Clin Oncol. 2015;33(suppl 7) abstr 140.

6.)  Fizazi K, Laplanche A, Lesaunier F:
Docetaxel-estramustine in localized high-risk prostate cancer: results of the French Genitourinary Tumor Group GETUG 12 phase III trial.
Proc Am Soc Clin Oncol. 2014;32(suppl) abstr 5005.

7.)  Fizazi K, Faivre L, Lesaunier F:
Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
Lancet Oncol. 2015;16:787–794

8.)  Schweizer MT, Huang P, Kattan MW, Kibel AS, De Wit R, Sternberg CN:
Adjuvant leuprolide with or without docetaxel in patients with high-risk prostate cancer after radical prostatectomy (TAX-3501).
Cancer. 2013;119:3610–3618

9.)  Sandler HM, Hu C, Rosenthal SA:
A phase III protocol of androgen suppression (AS) and 3DCRT/IMRT versus AS and 3DCRT/IMRT followed by chemotherapy (CT) with doxetaxel and prednisone for localized, high-risk prostate cancer (RTOG 0521)
Proc Am Soc Clin Oncol. 2015;33(suppl) abstr LBA5022.

blauer Punkt

Impressum                         Zuletzt geändert am 17.01.2015 23:04